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tumors (GEP-NET) represent a rare subclass of all 
gastrointestinal tumors. Because their aggressive-
ness and growth patterns vary greatly, from nearly 
benign to highly malignant, their classification is in 
continuous development: the revised Word Health 
Organization (WHO) classification [1] has character-
ize GEP-NET into:
- Well-differentiated endocrine tumors,
- Well-differentiated endocrine carcinomas,
- Poorly differentiated endocrine carcinomas.
Due to slow progress, carcinoid patients may 
have non-specific abdominal pain and diarrhoea 
for several years before diagnosis. Many patients 
get increased abdominal pain attacks with time, and 
approximately 40% are discovered at emergency 
surgery for intestinal obstruction. In other patients 
the diagnosis is settled after detection of liver me-
tastases, sometimes together with features of the 
carcinoid syndrome, which initially may be discrete 
with flush induced after intake of certain food or 
alcohol [6].
The most common symptom in fact is flushing, 
occurring in up to 94% of patients. Flushing has 
been linked to several factors including serotonin, 
tachykinins, and histamine. It can be provoked by 
cheese, wine, nuts, and stress. Diarrhea is the next 
most common manifestation of carcinoid syn-
drome, occurring in 80% of patients. Other symp-
toms include bronchial constriction and wheezing, 
abdominal pain, and pellagra (niacin deficiency). 
Carcinoid heart disease develops in 40% to 50% of 
patients with the syndrome. It’s characterized by 
plaquelike deposits of fibrous tissue on the tricus-
pid and pulmonary valves and the endocardium. 
Plaque formation causes endocardial thickening, 
which in turn causes retraction and fixation of the 
valves, leading to valvular dysfunction. This disease 
predominantly affects the right side of the heart, as 
the lungs are able to deactivate the serotonin before 
entering the left atrium. However, left-sided disease 
has been reporter.
The detection of GEP-NET metastases can be 
done with different techniques and so the sensitivi-
ties of detection of liver metastases vary on the basis 
of technique chosen. A recent study shows that they 
may be detected using US, SRS, CT, and MR with 
sensitivities of 46% [10], 49,3%, 78,5%, and 95,2% 
respectively [11].
In literature radiological differences between 
hepatic lesions of CTum and PET populations are not 
clearly underlined; moreover consensus is not easily 
found to distinguishing radiological CT findings pre-
sentation of lesions; some authors in facts recently 
considered that CT can not differentiate liver metas-
tases due to NET from any other malignant tumors 
[12]. This is due to the variability of behavior of these 
lesions; in fact they are generally well vascularised 
and best depicted during i.v. contrast enhancement 
in the portal venous inflow phase where they show 
up as high attenuating lesions in the non-enhanced 
normal liver.
As with the primary tumor, carcinoid metasta-
ses are usually of low density on noncontrast CT [2]; 
they are typically lesions and so well visualized as 
avidly enhancing masses during the early (arterial) 
phase of multiphasic contrast-enhanced CT. 
Hollett and colleagues [19] showed that the 
HAP (hepatic arterial dominant phase) images 
improved conspicuity in 39% of patients with a 
variety of metastatic lesions usually considered to 
be hypervascular. They demonstrated also that HAP 
imaging should be performed in patients suspected 
of having metastatic carcinoid to the liver, because 
approximately two-thirds of carcinoid metastases 
were either uniformly or heterogeneously hyperat-
tenuating during the HAP, approximately one-third 
of lesions were most conspicuous during the HAP, 
and approximately one-sixth of lesions were visible 
only during the HAP. In approximately one-third of 
patients, the HAP images, which showed more le-
sions than either the non-contrast phase or the PVP, 
were judged to be best for overall lesion detection 
[14].
Purpose
Due to the extreme variability and insidious 
presentation of GPNET (Gastropancreatic neuroen-
docrine tumors) hepatic metastases are present at 
time of diagnosis in a considerable percentage of 
cases. Because presence of liver involvement and 
number of lesions are recognize as independent 
prognostic factors, their detection is of tremendous 
importance. MR imaging has been shown the most 
sensitive imaging modality for liver metastases 
including neuroendocrine liver metastases but CT 
still plays a major role in oncologic patients, for sur-
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veillance and detection. However few study exists 
regarding CT findings of liver metastases from NET. 
Therefore the aime of our works was first to describe 
morphologic features and vascular behavior of carci-
noid and pancreatic metastases, second to look for 
differences between carcinoid and TEP metastases 




We retrospectively evaluated a list of 1015 pa-
tients hospitalized in the pancreatic unit of Beaujon 
hospital – Paris – France. We excluded 937 patients 
for the following reasons: patients evaluated before 
2004 (year of PACS Imaging installation) (n = 505); pa-
tients with other associated tumors (n = 10); already 
treated (n = 61); without CT exams (n = 28), without 
abdominal CT (n = 127) or without correct triphasic 
CT exam (n = 11); without hepatic metastases (n = 
136) and with other endocrine tumors or not iden-
tified endocrine tumors (n = 59).
Target population
Over a period of 64 months (January 2004 – 
December 2009) we used the PACS system of our 
hospital to retrospectively analyze patients who had 
previously untreated liver metastases originated 
from carcinoid or pancreatic endocrine tumors. 
We identified 78 consecutive patients (35 wo-
men and 43 men, mean age, 55,7 years min 20 Max 
81 years old; 13,36 standard deviation) referred for 
CT evaluation of secondary neoplastic involvement 
of the liver. All patients had a histological diagnosis 
of pancreatic endocrine tumors or carcinoid tumors 
based on histological analysis of specimens from 
either the primary site or the liver.
Diagnostic confirmations
The diagnosis of primary neuroendocrine tu-
mors carcinoid (n = 33) or pancreatic (n = 45) was 
histological. In all patients the most part of lesions 
allowed the typical malignant behavior at triphasic 
CT. However some lesions presented an atypical 
behavior (FNH-like behavior); in this case malignant 
behavior was confirmed on follow-up with evidence 
of an increase in size, the apparition of a portal veno-
us wash out or with a complementary exam (MRI).
FNH-like lesions
On the basis of observed data we noted a 
group of 20 patients with the presence of 51 hepatic 
metastases mimicking FNH-like nodules defined 
as nodules with well-defined contours and with a 
homogeneous arterial enhancement without portal 
venous washout. We analyzed this group focusing 
our attention on sex of patients, primitive tumor, 
size and number of FNH-like lesions, technique of 
confirmation of malignant nature of these lesions.
Results
Characteristics of patients
The characteristics of the 78 remaining patients 
enrolled into this retrospective study are listed in 
table 1. Briefly, the studied population included 43 
men (55 %) and 35 women (45 %). The mean +/- SD 
age was 55,8 +/- 13.1 years, range: 20–81 years (men 
57,9 +/- 14,3 range 20-81, women 53,2 +/- 11,9 range 
33-78) at the time of first complete imaging work-up 
of metastatic disease.
Concerning primary, 42 % arose from the pan-
creas (33 patients) and 58 % arose from the ileum (45 
patients); The primitive tumour had been removed 
at time of imaging in 35 (45 %) cases, including 16 
cases (48,5%) in the carcinoid tumour group and 
19 cases (42 %) in the pancreatic endocrine tumour 
group. Metastases revealed the malignancy in 21 
(7%) cases. 
Synchronous and metachronous metastases 
were observed in 48 (62 %) and 30 (38 %) patients 
respectively.
Morphological characteristics and enhancement 
behavior of liver metastases
Metastases showed heterogeneous contrast 
intake in 56 patients (72 %), including 28 patients (85 
%) with carcinoid tumour and 28 (62 %) patients with 
pancreatic endocrine tumour. Cystic components 
and target sign were found respectively in 59 (76 %) 
and 34 ( 44%) patients, including 28 / 11 (85% / 33%) 
patients with carcinoid tumour and 31/23 (65 % / 51 
%) patients with pancreatic endocrine tumour. 
Enhancement pattern
Liver metastases presented the classic washin 
/washout pattern in 37% of cases. The three next 
frequent pattern were hyper-isointense (20,1 %), 
iso-hypointense (17,2 %) and hypo-hypointense 
(15,7 %). 
Single pattern was seen in 38 patients whereas 
40 patients showed metastases with multiple pat-
terns. Among those patients with multiple pattern, 
the 2 most frequent associations were first hyper-
isointense and hyper-hypointense pattern (20,7 %) 
and second iso-hypointense and hyper-hypointense 
pattern (15,9 %).
Best phase for detection
In 50 (64%) of 78 patients, lesions were more 
conspicuous and better defined on contrast-enhan-
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ced arterial phase. Difference between both arterial 
and portal phase were much more obvious in PET 
group where the arterial phase was the best phase 
in up to 80 % of cases.
FNH-like lesion
51 FNH-likes lesions were depicted in 20 pa-
tients (9 men, 11 women). Mean ± SD size was 9.7 
cm ± 2.6 cm. The primitive tumour was a carcinoid 
in 5 cases and a PET in 15 cases. Confirmation of 
the malignant nature of the lesions was obtained 
by change in appearance and/or size in 16 cases, 
surgery in 1 cases and other technique (MRI, DWI) 
in 3 cases. 
Discussion
To our knowledge, our series is the largest series 
of liver metastases secondary to neuroendocrine tu-
mors (NET) evaluated on MDCT that has been repor-
ted in the literature. Despite the fact that MR imaging 
has been shown the most sensitive imaging modality 
for liver metastases including neuroendocrine liver 
metastases, CT plays a major role in diagnosing liver 
metastases as it is currently performed in oncologic 
patients for surveillance and in patients with various 
abdominal symptoms  [24, 25]. Interestingly, we have 
found a limited number of articles that have focused 
on CT findings of liver metastases from NET  [8, 10, 
11, 14, 16, 25, 26]. It is generally known that most 
neuroendocrine liver metastases are hypervascular 
but prevalence of this pattern and the others has 
not been described. Thus, we aimed to describe 
the different CT patterns of neuroendocrine liver 
metastases in patients with endocrine tumors of the 
pancreas and carcinoid tumors.
Our study based on analysis of 559 lesions, 
confirms that most neuroendocrine liver metastases 
were hypervascular (69%) on arterial phase imaging 
and hypo-attenuated (73%) on portal venous phase. 
However, only 37% of the lesions shared these two 
findings. Besides this typical appearance, the second 
most common pattern was composed of neuroen-
docrine liver metastases that were hypervascular on 
arterial phase imaging but did not exhibit wash-out 
(25%). This finding which has already been described 
in Dromain’s paper suggests that the wash-out sign 
has a low sensitivity in neuroendocrine liver metas-
tases [24]. Other neuroendocrine liver metastases 
were not hypervascular on arterial phase imaging 
but were hypo-attenuated (33%) on portal venous 
phase. These various presentations reinforce the 
complementary role of portal-venous phase ima-
ging.
It is usually considered that neuroendocrine 
liver metastases from pancreatic tumors and from 
carcinoid tumors have a similar presentation  [12]. 
Our results disagree with this statement as we have 
seen that lesions from carcinoid tumors (87.5%) 
are more often hypo-attenuated on portal venous 
phase than those from pancreatic tumors (56%). 
Indeed, this explains why we have found that liver 
metastases from carcinoid tumors were best seen 
on portal venous-phase in 58%, conversely to liver 
metastases from pancreatic tumors which were best 
seen on arterial phase MDCT in most (80%) cases. 
In a series of hypervascular liver metastases from 
various origin (breast carcinoma, neuroendocrine 
tumor, melanoma, renal cell carcinoma, and thyroid 
carcinoma) more lesions were detected on portal 
venous phase imaging  [26]. These authors have 
also demonstrated that combination of unenhanced 
plus portal venous phase images allowed detection 
of statistically significantly more hypervascular liver 
metastases than combination of arterial phase plus 
portal venous images  [26]. In a series of 31 patients 
with proved carcinoid liver metastases, more lesions 
(although not significant) were detected on portal 
venous phases  [14]. Then, hypervascularity on arte-
rial phase imaging when present is a key finding in 
neuroendocrine liver metastases. Yet, neuroendo-
crine liver metastases may lack hypervascularity. In 
these cases, portal venous phase is especially helpful 
for detection and characterization.
Interestingly, we have seen liver metastases that 
had a focal nodular hyperplasia-like appearance in 
23/78 patients. We are not aware of any published 
data on this topic. We defined FNH-like lesion as 
lesions that were isoattenuating on unenhanced CT 
scan, hypervascular and homogeneous on arterial 
phase imaging and iso-attenuating on portal-venous 
phase. As small FNHs may lack central scar, we did not 
consider this finding for FNH-like lesions. One could 
argue that FNHs may coexist in patients with liver 
metastases and these lesions could be benign ones. 
Yet most of our FNH-like lesions were confirmed as 
liver metastases either on pathology or on significant 
increase on follow-up or significant decrease under 
treatment. We want to stress this new pattern as its 
recognition may change patient management. 
Our study has limitations. First, our study design 
was retrospective, but we selected all consecutive 
patients diagnosed with liver metastases from NET 
who had MDCT, which limits the possibility of sam-
pling bias. Furthermore all patients had the same 
CT protocol which strengthens the results. Second, 
not all patients had pathologic confirmation of their 
neuroendocrine liver metastases. As most patients 
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have diffuse liver involvement, surgical resection is performed in a minority of the cases and this could have 
biases our results. Third, we did not perform independent readings of CT examinations. Our intent was not 
to primarily assess which phase was best in neuroendocrine liver metastases but rather to describe in a large 
series of neuroendocrine liver metastases originating from pancreatic tumors and carcinoid tumors.
Arterial phase Portal phase
Lesion is hyperattenuated at arterial phase and isoattenuated 
at portal venous phase without portal venous washout.
Fig. 1. Typical behavior  of FNH-like nodules.
Arterial phase Portal phase Arterial phase Portal phase
First typical pattern of endocrine metastases . Note 
hypervascular enhancement at arterial phase and the 
hypovascular washout at portal venous phase.
Second typical pattern of endocrine metastases. Note that lesions 
of smaller size can be detected only by visualisation of  portal 
venous washout.
Fig. 2. Vascular Patterns
Pattern of enhancement among 78 patients
Arterial phase Portal phase Freq. Pattern % Pattern PET Carcinoid
1 hyperintense hypointense 50 37,3% 29 21
2 hyperintense isointense 27 20,1% 20 7
3 isointense hypointense 23 17,2% 10 13
4 hypointense hypointense 21 15,7% 8 13
5 hyperintense hyperintense 7 5,2% 5 2
6 isointense isointense 3 2,2% 1 2
7 hypointense isointense 1 0,7% 0 1
8 hypointense hypointense 1 0,7% 1 0
9 isointense hyperintense 1 0,7% 0 1
134 100% 74 60
Conclusion
In conclusion, our large series shows that a minority of patients had neuroendocrine liver metastases 
that were hypervascular on arterial phase imaging and hypo-attenuating on portal venous phase. Recogni-
tion of the other patterns is mandatory. We have also shown for the first time that these metastases could 
have FNH-like appearance. 
References
1. Rindi G., C. Capella and E. Solcia. Introduction to a revised clinicopathological classifi cation of neuroendocrine tumors 
of the gastroenteropancreatic tract. In: Q. J. Nucl. Med., 2000, 44(1): 13-21.




C O N G R E S
3. Buetow P.C., et al. Islet cell tumors of the pancreas: clini-
cal, radiologic, and pathologic correlation in diagnosis 
and localization. In: Radiographics, 1997, 17(2): 453-
472; quiz 472A-472B.
4. Metz. D.C. and R.T. Jensen. Gastrointestinal neuroen-
docrine tumors: pancreatic endocrine tumors. In: Gas-
troenterology, 2008, 135(5): 1469-1492.
5. Pasieka J.L., Carcinoid tumors. In: Surg. Clin. North Am., 
2009, 89(5): 1123-1137.
6. Akerstrom G. and P. Hellman. Surgery on neuroendo-
crine tumours. Best Pract. Res. Clin. Endocrinol. Metab., 
2007, 21(1): 87-109.
7. Scigliano S., et al. Clinical and imaging follow-up after 
exhaustive liver resection of endocrine metastases: a 15-
year monocentric experience. In: Endocr. Relat. Cancer, 
2009, 16(3): 977-990.
8. Durante C., et al. Prognostic factors infl uencing survival 
from metastatic (stage IV) gastroenteropancreatic well-
diff erentiated endocrine carcinoma. In: Endocr. Relat. 
Cancer, 2009, 16(2): 585-597.
9. Nissen N.N., et al. Pancreatic neuroendocrine tumors: 
presentation, management, and outcomes. In: Am. 
Surg., 2009, 75(10): 1025-1029.
10. Sutcliff e R., et al. Management of neuroendocrine liver 
metastases. In: Am. J. Surg., 2004, 187(1): 39-46.
11. Dromain C., et al. Detection of liver metastases from 
endocrine tumors: a prospective comparison of soma-
tostatin receptor scintigraphy, computed tomography, 
and magnetic resonance imaging. In: J. Clin. Oncol., 
2005, 23(1): 70-78.
12. Sundin A., et al. ENETS Consensus Guidelines for the 
Standards of Care in Neuroendocrine Tumors: radiologi-
cal examinations. In: Neuroendocrinology, 2009, 90(2): 
167-183.
13. Rockall A.G. and R.H. Reznek. Imaging of neuroen-
docrine tumours (CT/MR/US). In: Best Pract. Res. Clin. 
Endocrinol. Metab., 2007, 21(1): 43-68.
14. Paulson E.K., et al. Carcinoid metastases to the liver: role 
of triple-phase helical CT. In: Radiology, 1998, 206(1): 
143-150.
15. Foley W.D., et al. Multiphase hepatic CT with a multi-
row detector CT scanner. In: Am. J. Roentgenol., 2000, 
175(3): 679-685.
16. Seemann M.D., et al. Assessment of the extent of 
metastases of gastrointestinal carcinoid tumors using 
whole-body PET, CT, MRI, PET/CT and PET/MRI. In: Eur. 
J. Med. Res., 2006, 11(2): 58-65.
17. Berge T., and F. Linell, Carcinoid tumours. Frequency in 
a defi ned population during a 12-year period. In: Acta 
Pathol. Microbiol. Scand. A., 1976, 84(4): 322-330.
18. Wong M., et al. Radiopathological review of small bowel 
carcinoid tumours. In: J. Med. Imaging Radiat. Oncol., 
2009, 53(1): 1-12.
19. Hollett M.D., et al. Dual-phase helical CT of the liver: 
value of arterial phase scans in the detection of small 
(< or = 1.5 cm) malignant hepatic neoplasms. In: Am. 
J. Roentgenol., 1995, 164(4): 879-884.
20. Rha S.E., et al. CT and MR imaging fi ndings of endocrine 
tumor of the pancreas according to WHO classifi cation. 
In: Eur. J. Radiol., 2007, 62(3): 371-377.
21. Kwekkeboom D.J., et al. Somatostatin analogue scin-
tigraphy in carcinoid tumours. In: Eur. J. Nucl. Med., 
1993, 20(4): 283-292.
22. Semelka R.C., et al. Islet cell tumors: comparison of 
dynamic contrast-enhanced CT and MR imaging with 
dynamic gadolinium enhancement and fat suppression. 
In: Radiology, 1993, 186(3): 799-802.
23. Janson E.T., et al. Carcinoid tumors: analysis of prognos-
tic factors and survival in 301 patients from a referral 
center. In: Ann. Oncol., 1997, 8(7): 685-690.
24. Dromain C., et al. MR imaging of hepatic metastases 
caused by neuroendocrine tumors: comparing four 
techniques. In: Am. J. Roentgenol., 2003, 180(1): 121-
128.
25. Elias D., et al. Hepatic metastases from neuroendocrine 
tumors with a “thin slice” pathological examination: 
they are many more than you think. In: Ann. Surg., 2010, 
251(2): 307-310.
26. Oliver J.H., 3rd, et al. Hypervascular liver metastases: 
do unenhanced and hepatic arterial phase CT images 
aff ect tumor detection? In: Radiology, 1997, 205(3): 
709-715.
VALOAREA EXAMINĂRII PRIN TOMOGRAFIE 




Introducere. Pancreatita acută, greu de dia-
gnosticat în primele momente din cauza factorilor 
etiologici multipli, fiziopatogenezei complexe, nece-
sită un raţionament medical privind diagnosticul de 
urgenţă, fiind necesară o decizie rapidă, formulată 
după o evaluare clinică, de laborator și imagistică. 
La aplicarea unui tratament timpuriu, pancreatita 
acută evoluează favorabil și doar în 20% din cazuri 
boala are o evoluţie severă, degenerând în pancre-
atită necrotico-hemoragică. O valoare indiscutabilă 
în determinarea gradului de extindere a procesului 
inflamator pancreatic îl au examinările imagistice.
Scopul studiului: evaluarea tomografiei com-
puterizate (TC) spiralate în diagnosticul pancreatitei 
acute.
Materiale și metode. Pentru aprecierea va-
lorii metodelor imagistice de diagnostic (ecografie 
abdominală și tomografie computerizată) în apreci-
erea gradului de extindere a procesului inflamator 
pancreatic, am considerat utilă analiza retrospectivă 
a 47 de pacienţi care s-au adresat în departamentul 
de urgenţă al IMSP Centrul Știinţifico-Practic de Me-
dicină Urgentă din municipiul Chișinău.
Concluzii. Se înregistrează o incidenţă sporită 
a pancreatitei acute la persoanele apte de muncă, 
cu o răspândire mai înaltă în regiunea de Centru 
a republicii, cu prevalare în localităţile urbane. Di-
agnosticul pancreatitei acute trebuie definitivat în 
primele 48 de ore de la debutul bolii, pentru preîn-
